Neuronal Surface Autoantibodies in Neuropsychiatric Disorders: Are There implications for Depression?

Shenghua Zong, Carolin Hoffmann, Marina Mane-Damas, Peter Molenaar, Mario Losen, Pilar Martinez-Martinez*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Autoimmune diseases are affecting around 7.6-9.4% of the general population. A number of central nervous system disorders, including encephalitis and severe psychiatric disorders, have been demonstrated to associate with specific neuronal surface autoantibodies (NSAbs). It has become clear that specific autoantibodies targeting neuronal surface antigens and ion channels could cause severe mental disturbances. A number of studies have focused or are currently investigating the presence of autoantibodies in specific mental conditions such as schizophrenia and bipolar disorders. However, less is known about other conditions such as depression. Depression is a psychiatric disorder with complex etiology and pathogenesis. The diagnosis criteria of depression are largely based on symptoms but not on the origin of the disease. The question which arises is whether in a subgroup of patients with depression, the symptoms might be caused by autoantibodies targeting membrane-associated antigens. Here, we describe how autoantibodies targeting membrane proteins and ion channels cause pathological effects. We discuss the physiology of these antigens and their role in relation to depression. Finally, we summarize a number of studies detecting NSAbs with a special focus on cohorts that include depression diagnosis and/or show depressive symptoms.

Original languageEnglish
Article number752
Number of pages12
JournalFrontiers in Immunology
Volume8
DOIs
Publication statusPublished - 5 Jul 2017

Keywords

  • neuronal surface autoantibodies
  • neuropsychiatric disorders
  • depression
  • pathogenicity
  • immuno-globulin
  • neurotransmitter receptor
  • ion channel
  • blood-brain barrier
  • D-ASPARTATE RECEPTOR
  • SYSTEMIC-LUPUS-ERYTHEMATOSUS
  • DOPAMINE D2 RECEPTOR
  • COMPLEMENT-MEDIATED CYTOTOXICITY
  • ANTI-NMDAR ENCEPHALITIS
  • CENTRAL-NERVOUS-SYSTEM
  • LIMBIC ENCEPHALITIS
  • GLUTAMATE-RECEPTOR
  • AMPA RECEPTOR
  • MYASTHENIA-GRAVIS

Cite this